Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Locoregional immunotherapy in cancer patients: Review of clinical studies (2000)
    Springer
    Annals of oncology 11 (2000), S. 1229-1239 
    Details
    ISSN: 1569-8041
    Keywords: adoptive cell transfer ; cancer ; interferons ; interleukin-2 ; locoregional immunotherapy ; review
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Many patients with invasive cancer have a compromised immune system. Thisimmune dysfunction does appear to start at the site of the tumor. Locoregionalimmunotherapy is given to stimulate the immune system in order to kill tumorcells either indirectly via a specific or a non-specific way or directly viacell transfer therapy. Advantages to give this immunotherapy locoregionallyin stead of systemically are a higher concentration of the immunomodulator atthe site of the tumor, to attract or activate effector cells, and diminishedtoxicity. In this review we have summarised the clinical studies usingloco-regional immunotherapy in patients with cancer. Only phase I and IIstudies were performed. Clinical responses were seen. No single locoregionaltreatment has become a standard therapy. Relatively few investigations wereperformed to estimate the influence on the locally effector mechanisms orimmune dysfunction. In future clinical trials it is essential to get a betterinsight in these mechanisms.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008335318764
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-α as second-line treatment of advanced transitional cell cancer of the urothelial tract (2000)
    Springer
    Annals of oncology 11 (2000), S. 1391-1394 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; interferon ; transitionall-cell carcinoma ; urothelial tract
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:Based on the favorable results of the combination5-fluorouracil (5-FU), cisplatin and interferon-α as second-line treatmentin advanced metastatic transitional-cell carcinoma of the urothelial tract aconfirmatory study was executed in a multicenter setting. Patients and methods:In this open label phase II study 43patients failing adequate previous chemotherapy were treated with IFN-α2b5 MU/m2 subcutaneously for 5 consecutive days starting on day 1 and22 simultaneous with 5-FU 500 mg/m2 daily as a continuous infusion.In between the same dose of IFN-α2b was given 3 times weekly with CDDP 25mg/m2 on days 1, 8, 15 and 22. This cycle was repeated every sixweeks. Results:In 40 eligible patients 5 PR were seen (12.5%;95% confidence interval (95% CI):4.1%–26.8%). The major toxicity was hematological. Twotoxic deaths were seen due to gastro-intestinal hemorrhage. Conclusions:In view of these results this combination can not berecommended as second line treatment for metastatic transitional-cellcarcinoma of the urothelial tract.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1026589120989
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...